Posts

New Study Aims to Unlock Clues from Cancer Survivors’ Immune Systems

British biotech company Etcembly has launched a new research study, aiming to discover new cancer therapy targets by examining the immune cells of cancer...

Study Sheds Light on How Genes Influence Protein Levels in the Body

A study in Nature Genetics offers fresh insights into how genetic differences affect the levels of proteins in our bodies. This research, part of...

New Study Points to BRD9 as a Potential Target for Gallbladder Cancer Treatment

Gallbladder cancer is a highly aggressive cancer with a poor prognosis, and most patients are diagnosed too late for effective treatment. A study published...

Pairwise Raises $40M in Funding to Improve Crop Breeding

Pairwise, a company using gene-editing technology to improve crop breeding, has raised $40 million in its latest funding round. Led by Deerfield Management, the...

Thermo Fisher Expands Lab Services with New Facility in Sweden

Thermo Fisher Scientific is set to open a new bioanalytical lab in Gothenburg, Sweden, as part of an expansion of its global laboratory services....

NTx Launches New mRNA Production Service, Offering Faster and More Flexible Solutions

Nature’s Toolbox (NTx), has introduced a new service called NTx Services. This service aims to streamline the production of high-quality mRNA using the company’s...

ONI Expands into Lipid Nanoparticle Research with Advanced Imaging Technology

ONI, is stepping into the growing field of lipid nanoparticle research. LNPs are crucial for delivering therapies like mRNA vaccines and gene therapies, and...

Genomes.io Launches Feature to Help Users Secure and Control Their DNA Data

In response to growing concerns about privacy and the misuse of personal genetic data, Genomes.io has introduced a new feature allowing users to upload...

New Data Highlights Predictive Power of Natera’s Signatera Test for Colorectal Cancer

Natera, Inc., has unveiled new findings from the GALAXY arm of the CIRCULATE-Japan trial at the 2024 European Society for Medical Oncology (ESMO) Congress...

Merck’s KEYTRUDA Shows Promising Results in Survival for Early-Stage Triple-Negative Breast Cancer

Merck & Co., has shared new findings from its Phase 3 KEYNOTE-522 trial, showing that its immunotherapy drug KEYTRUDA, when combined with chemotherapy, can...